PReS-FINAL-2061: Abatacept in therapy of juvenile idiopathic arthritis in real clinical practice

Benzer Materyaller

• Ten years of experience of biologics in juvenile idiopathic arthritis: focus for the reasons of withdrawals
  Yazar:: Arsenyeva, Svetlana V, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• PReS-FINAL-2076: Single centre experience of biologics in clinical practice of systemic juvenile idiopatic arthritis
  Yazar:: Kaleda, MI, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• PReS-FINAL-2014: Excellent results of the conventional treatment in a child with late-diagnosed juvenile dermatomyositis with severe calcinosis
  Yazar:: Nikishina, IP, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• PReS-FINAL-2062: The need for conducting different rehabilitation complexes for patients with juvenile idiopathic arthritis (JIA)
  Yazar:: Shelepina, TA, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• PReS-FINAL-2138: Abatacept (orencia) in treatment of different types of juvenile idiopathic arthritis
  Yazar:: Zholobova, ES, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)